Week of October 19, 2026

One of the largest U.S. independent oil and gas producers, with big Permian, Alaska and LNG assets.

Setup

New 3-month closing high at $146.51 (+9.3% on the week, +26.7% over 3 months), well above its 20-day average (~$131.64). Energy was a top S&P 500 sector this week as Brent hit $110 for the first time since May.

Levels

Entry $142-147Stop $135 (below this week's low)Target $158

Catalyst

Oil headlines from Hormuz and Russia/Ukraine; Q3 results Nov 5.

Risk

Very extended; a de-escalation headline could knock crude and the stock lower fast.

Aerospace and defense giant behind Raytheon missiles, Pratt & Whitney engines and Collins Aerospace.

Setup

Jumped 3.7% Friday to $193.92 on about 1.8x normal volume, reclaiming its 20-day average (~$187). Fresh Navy and Pentagon awards (SM-6 deal worth up to $24.4B, SM-3 up to $6.3B) plus Middle East tensions are pulling money into defense.

Levels

Entry $189-195Stop $180.50Targets $200 (50-day average), then $210

Catalyst

Q3 earnings Tue, Oct 20 before the open.

Risk

Earnings next week is a coin flip; the stock is still below its 50-day average.

The world's largest retailer, with a fast-growing e-commerce and advertising business.

Setup

Up 6.7% on the week and 11.3% over a month to $118.81, above its 20- and 50-day averages, as money rotates from tech into defensive leaders. It is pressing against its 3-month high of $121.38.

Levels

Entry $116-120, or add on a close above $121.38Stop $110.90Targets $128, then $134 (record close)

Catalyst

Defensive rotation while tech is under pressure.

Risk

If tech bounces hard, defensive leaders can lag.

Global prestige beauty company (Estee Lauder, Clinique, MAC, La Mer) in the middle of a turnaround.

Setup

Up 25% over 3 months to $104.54 after a fiscal Q4 beat (organic sales +5%). Barclays upgraded it to Overweight ($108 target) and Morgan Stanley raised its target to $112.

Levels

Entry $100-105Stop $95.90Target $112

Catalyst

Analyst upgrades; fiscal Q1 results Nov 2.

Risk

China and travel-retail demand is still uneven; it pulled back 2.5% Friday from a 3-month high.

The largest U.S. health insurer (UnitedHealthcare) plus the Optum health-services and pharmacy business.

Setup

Beat Q3 estimates ($4.69 adjusted EPS vs about $4.13 expected) and raised its 2026 outlook to at least $20.50. The stock closed at $401.43, back above its 50-day average (~$387), on about 2x normal volume this week.

Levels

Entry $392-405Stop $371.90Target $437 (3-month high)

Catalyst

Managed-care rally after the 2027 Medicare Star Ratings; follow-through after the beat.

Risk

Lower Star Ratings could cut 2028 bonus payments; policy headlines hit the group fast.

The world's largest contract chipmaker; it builds the leading-edge chips for Nvidia, Apple, AMD and others.

Thesis

Quality compounder on sale. Q3 revenue rose 50.9% year over year with a 66.4% gross margin, and Q4 guidance ($52.3-54.3B) points higher. Yet the shares are down about 15% from the $487.47 high in the AI sell-off.

Catalyst

AI chip demand and TSMC's monthly sales reports.

Risk

AI spending pullback, Taiwan geopolitics.

Software and cloud leader (Azure, Office 365, Windows), and a major AI platform.

Thesis

Durable compounder with recurring revenue and huge cash flow; buy on weakness during the AI-trade wobble. It is about 4% below its recent $551 high.

Catalyst

Fiscal Q1 earnings Oct 28 (Azure growth, AI revenue, capex).

Risk

Fiscal 2026 capex was about $175B and rising; investors may punish more spending.

Maker of the FICO credit score and decisioning/fraud software used by most U.S. lenders.

Thesis

Beaten down: about 39% lower over 3 months, after regulators let lenders use VantageScore on equal terms. Early signs the moat holds: United Wholesale Mortgage will keep pulling FICO on every broker loan. A 15% job cut should protect margins. Shares rebounded 15.5% this week.

Catalyst

Lender adoption news; fiscal Q4 results in early-to-mid November.

Risk

Further mortgage share loss to VantageScore; over $5B of debt.

A leading Medicare Advantage insurer serving seniors.

Thesis

Re-rate story. 95% of members will be in 4-star-or-better plans for 2027, up from 20% for 2026, which Evercore estimates could bring about $4.8B in 2028 bonus payments. The stock is about 9% off its $456.50 high.

Catalyst

Q3 results Nov 6; 2027 enrollment and pricing.

Risk

Already priced richly (about 25x forward earnings by one estimate); Medicare policy risk.

The world's largest athletic footwear and apparel brand.

Thesis

Deep-value turnaround. It hit a 13-year low after revenue fell 4%, and it has a $2.5B cost plan. If the brand stabilizes, today's price could look cheap in 2-3 years. This is a patient, speculative idea, not a quick trade.

Catalyst

Investor Day Nov 17.

Risk

Analyst targets ($24-33) sit below the price; the cost savings mostly land in 2029-30.